Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319068 | 0.92 | CYP4F2 (0.51) | CYP4F2CYP4A11SMN1; SMN2KMT2AMAPT | |
| SCHEMBL6034901 | 0.91 | PTGS2 (0.56) | CYP4F2CYP4A11SMN1; SMN2KMT2AMAPT | |
| SCHEMBL229166 | 0.90 | SMN1; SMN2 (0.50) | CYP4F2CYP4A11SMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL17391139 | 0.89 | CYP4F2 (0.49) | CYP4F2CYP4A11SMN1; SMN2KMT2AMAPT | |
| SCHEMBL1052227 | 0.89 | PTGS2 (0.50) | CYP4F2CYP4A11SMN1; SMN2CYP4Z1ALOX5 | |
| SCHEMBL5276845 | 0.87 | CNR1 (0.50) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL27430803 | 0.86 | CYP4F2 (0.56) | CYP4F2CYP4A11KMT2ALMNAL3MBTL1 | |
| SCHEMBL1802183 | 0.84 | ALDH1A1 (0.56) | CYP4F2CYP4A11MAPTALDH1A1TDP1 | |
| SCHEMBL5884605 | 0.84 | KMT2A (0.51) | KMT2AMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL490909 | 0.83 | CYP4F2 (0.70) | CYP4F2CYP4A11KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728910-B | Pyrazole derivative for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111253314-B | Vinyl sulfonamide substituted pyrazolyl benzamides | 创沐医药科技(上海)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115819239-A | Intermediate of fibroblast growth factor receptor inhibitor and preparation method and application thereof | 无锡和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-111936470-B | Amidopyrazoles useful as irreversible FGFR inhibitors | 上海奕拓医药科技有限责任公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-110317173-B | Amidopyrazoles useful as irreversible FGFR inhibitors | 上海奕拓医药科技有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3261637-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-111072638-B | Method for preparing AZD4547, intermediate and preparation method of intermediate | 上海工程技术大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-112441980-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | CYP4F2 2918/4885CYP4A11 1424/4885SMN1; SMN2 3702/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | CYP4F2 35/4885CYP4A11 11/4885SMN1; SMN2 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.